

 Early Warning System

EIB-20230605

NORLASE RDI (IEU LS)



Quick Facts

Countries	Denmark
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2024-12-20
Borrower	NORLASE APS
Sectors	Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 20.86 million
Project Cost (USD)	\$ 45.90 million



Project Description

According to the Bank's website, the project supports the development and market access of innovative portable ophthalmic lasers to diagnose and treat causes of vision loss and blindness. Key project elements are novel eye laser technologies, including expansion of production facilities.

The project will support the promoter's investments in Research, Development, and Innovation (RDI) to advance its new eye laser treatment as well as other innovative medical devices based on novel laser technology. The project also includes capital expenditure (capex) and market access costs.



Early Warning System Project Analysis

According to the Environmental and Social Data Sheet: Based on the environmental, climate and social information and based on the review of the likely significant environmental, climate and social risks and impacts and the mitigation measures and management systems in place, the Project is deemed to have low residual environmental, climate and social risks and impacts.



Investment Description

- European Investment Bank (EIB)

A €20 million venture debt financing.



Private Actors Description

Norlase was founded in Denmark to commercialize patented laser technology developed at the Technical University of Denmark (DTU) and its products are now in use in the top ophthalmic hospitals globally.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Norlase ApS	Client	-



Contact Information

Contact: Tim Smit

Email: t.smit@eib.org

Phone: + 352 4379 – 89076

ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>



Bank Documents

- [Environmental and Social Data Sheet \(ESDS\) - NORLASE RDI \(IEU LS\)](#)

Media

- [Denmark: Norlase secures €20 million EIB venture debt to advance ophthalmic laser technology.](#)



Other Related Projects

- EIB-20220302 LIFE SCIENCES (INVESTEU VD) PL